#BEGIN_DRUGCARD DB00512

# AHFS_Codes:
08:12.28.16

# ATC_Codes:
A07AA09
J01XA01

# Absorption:
Poorly absorbed from gastrointestinal tract, however systemic absorption (up to 60%) may occur following intraperitoneal administration.

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Vancocin
Vancocin HCL
Vancoled
Vancor

# CAS_Registry_Number:
1404-90-6

# ChEBI_ID:
28001

# Chemical_Formula:
C66H75Cl2N9O24

# Chemical_IUPAC_Name:
(1S,2R,18R,19R,22S,25R,28R,40S)-48-{[(2S,3R,4S,5S,6R)-3-{[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-22-(carbamoylmethyl)-5,47-dichloro-2,18,32,35,37-pentahydroxy-19-[(2R)-4-methyl-2-(methylamino)pentanamido]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2^{3,6}.2^{14,17}.1^{8,12}.1^{29,33}.0^{10,25}.0^{34,39}]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2241807

# Description:
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. [PubChem]

# Dosage_Forms:
Capsule	Oral
Capsule	Oral
Powder, for solution	Intravenous

# Drug_Category:
Anti-Bacterial Agents
Glycopeptide antibacterials

# Drug_Interactions:
Colistimethate	Additive nephrotoxic effects may occur. Consider alternate therapy or monitor for renal function during concomitant therapy.
Gallium nitrate	Additive nephrotoxic effects may occur. Avoid concomitant therapy.
Tobramycin	Increased risk of nephrotoxicity

# Drug_Reference:
10524959	Gonzalez C, Rubio M, Romero-Vivas J, Gonzalez M, Picazo JJ: Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis. 1999 Nov;29(5):1171-7.
12720556	Sivagnanam S, Deleu D: Red man syndrome. Crit Care. 2003 Apr;7(2):119-20. Epub 2002 Dec 23.
16323120	Levine DP: Vancomycin: a history. Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S5-12.
2393284	Small PM, Chambers HF: Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother. 1990 Jun;34(6):1227-31.
8038306	Cantu TG, Yamanaka-Yuen NA, Lietman PS: Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis. 1994 Apr;18(4):533-43.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-3.1

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Vancomycin

# HET_ID:
DVV

# Half_Life:
Half-life in normal renal patients is approximately 6 hours (range 4 to 11 hours). In anephric patients, the average half-life of elimination is 7.5 days.

# InChI_Identifier:
InChI=1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1

# InChI_Key:
InChIKey=MYPYJXKWCTUITO-LYRMYLQWSA-N

# Indication:
For the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci.

# KEGG_Compound_ID:
C06689

# KEGG_Drug_ID:
D00212

# LIMS_Drug_ID:
512

# Mechanism_Of_Action:
The bactericidal action of vancomycin results primarily from inhibition of cell-wall biosynthesis. Specifically, vancomycin prevents incorporation of N-acetylmuramic acid (NAM)- and N-acetylglucosamine (NAG)-peptide subunits from being incorporated into the peptidoglycan matrix; which forms the major structural component of Gram-positive cell walls. The large hydrophilic molecule is able to form hydrogen bond interactions with the terminal D-alanyl-D-alanine moieties of the NAM/NAG-peptides. Normally this is a five-point interaction. This binding of vancomycin to the D-Ala-D-Ala prevents the incorporation of the NAM/NAG-peptide subunits into the peptidoglycan matrix. In addition, vancomycin alters bacterial-cell-membrane permeability and RNA synthesis. There is no cross-resistance between vancomycin and other antibiotics. Vancomycin is not active in vitro against gram-negative bacilli, mycobacteria, or fungi.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
1449.254

# Molecular_Weight_Mono:
1447.430199787

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
1PNV

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA451850

# Pharmacology:
Vancomycin is a branched tricyclic glycosylated nonribosomal peptide produced by the fermentation of the Actinobacteria species <i>Amycolatopsis orientalis</i> (formerly <i>Nocardia orientalis</i>). It is often reserved as the "drug of last resort", used only after treatment with other antibiotics had failed. Vancomycin has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections: <i>Listeria monocytogenes</i>, <i>Streptococcus pyogenes</i>, <i>Streptococcus pneumoniae</i> (including penicillin-resistant strains), <i>Streptococcus agalactiae</i>, <i>Actinomyces</i> species, and <i>Lactobacillus</i> species. The combination of vancomycin and an aminoglycoside acts synergistically in vitro against many strains of Staphylococcus aureus, Streptococcus bovis, enterococci, and the viridans group streptococci.

# Predicted_LogP_Hydrophobicity:
1.11

# Predicted_LogS:
-3.8

# Predicted_Water_Solubility:
2.25e-01 g/l

# Primary_Accession_No:
DB00512

# Protein_Binding:
Approximately 55% serum protein bound.

# PubChem_Compound_ID:
14969

# PubChem_Substance_ID:
46505261

# RxList_Link:
http://www.rxlist.com/cgi/generic2/vancomycin.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01287
EXPT03217

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Vancomycin HCL

# Synthesis_Reference:
11579438	Boger DL. Vancomycin, teicoplanin, and ramoplanin: synthetic and mechanistic studies. Med Res Rev. 2001 Sep;21(5):356-81.

# Toxicity:
The oral LD<sub>50</sub> in mice is 5000 mg/kg. The median lethal intravenous dose is 319 mg/kg in rats and 400 mg/kg in mice.

# Update_Date:
2013-02-08 16:19:24 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Vancomycin

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11579438	Boger DL: Vancomycin, teicoplanin, and ramoplanin: synthetic and mechanistic studies. Med Res Rev. 2001 Sep;21(5):356-81.
2151441	Reynolds PE, Somner EA: Comparison of the target sites and mechanisms of action of glycopeptide and lipoglycodepsipeptide antibiotics. Drugs Exp Clin Res. 1990;16(8):385-9.
2532132	Reynolds PE: Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis. 1989 Nov;8(11):943-50.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
7159

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
Not Available

# Drug_Target_1_Name:
D-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycan

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
Not Available

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Not Available

# Drug_Target_1_SwissProt_Name:
Not Available

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
Not Available

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
15122882	Mulichak AM, Lu W, Losey HC, Walsh CT, Garavito RM: Crystal structure of vancosaminyltransferase GtfD from the vancomycin biosynthetic pathway: interactions with acceptor and nucleotide ligands. Biochemistry. 2004 May 11;43(18):5170-80.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
U84349

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
gtfA

# Drug_Target_2_Gene_Sequence:
>1191 bp
ATGCGCGTGTTGATTACGGGGTGTGGATCGCGCGGAGATACCGAACCGTTGGTGGCATTG
GCGGCACGGTTGCGGGAACTCGGTGCGGACGCGCGGATGTGCCTGCCGCCGGACTACGTG
GAGCGGTGCGCCGAGGTCGGTGTGCCGATGGTGCCGGTCGGTCGGGCGGTGCGCGCAGGG
GCACGCGAGCCGGGAGAACTGCCGCCGGGGGCGGCCGAAGTCGTGACCGAGGTGGTCGCC
GAATGGTTCGACAAGGTCCCGGCGGCCATCGAGGGGTGTGACGCGGTGGTGACGACCGGC
TTGCTGCCCGCCGCGGTCGCTGTCCGGTCGATGGCCGAGAAGCTGGGCATCCCGTACCGC
TACACCGTGCTGTCTCCGGACCATCTGCCGTCGGAGCAAAGCCAGGCGGAGCGGGACATG
TACAACCAGGGCGCCGACAGGCTTTTCGGTGACGCGGTCAACAGCCACCGGGCCTCGATC
GGCCTGCCACCGGTGGAGCACCTCTACGACTACGGCTACACCGATCAGCCCTGGCTGGCG
GCGGACCCGGTGCTGTCCCCGCTGCGGCCGACGGACCTCGGCACTGTGCAGACCGGTGCG
TGGATCCTGCCCGACGAACGGCCGCTTTCCGCGGAGCTGGAGGCGTTTCTGGCTGCCGGG
TCGACGCCGGTGTACGTGGGTTTCGGCAGCTCGTCCCGACCGGCAACCGCTGACGCCGCG
AAGATGGCCATCAAGGCGGTCCGTGCCAGTGGCCGCCGGATCGTTCTCTCCCGCGGCTGG
GCCGATTTGGTCCTGCCGGACGACGGGGCCGACTGCTTCGTGGTCGGCGAAGTGAACCTT
CAGGAGCTGTTCGGCCGGGTGGCCGCCGCCATCCACCACGACAGCGCGGGCACGACGCTG
CTGGCCATGCGGGCGGGCATCCCCCAGATCGTGGTGCGCCGCGTAGTGGACAACGTGGTG
GAGCAGGCGTACCACGCCGACCGGGTGGCCGAGCTGGGTGTCGGTGTGGCGGTCGACGGT
CCGGTCCCGACCATCGACTCCTTGTCGGCCGCGCTCGACACGGCTCTGGCCCCGGAGATC
CGTGCGCGAGCGACGACCGTGGCAGACACGATTCGCGCCGATGGGACAACGGTGGCCGCG
CAGCTGCTGTTCGACGCGGTCAGCCTGGAAAAGCCGACTGTTCCCGCCTGA

# Drug_Target_2_General_Function:
Involved in transferase activity, transferring hexosyl groups

# Drug_Target_2_General_References:
Not Available

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
4790

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
41663

# Drug_Target_2_Name:
Glycosyltransferase GtfA

# Drug_Target_2_Number_of_Residues:
396

# Drug_Target_2_PDB_ID:
1PNV

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF03033	Glyco_transf_28

# Drug_Target_2_Protein_Sequence:
>Glycosyltransferase GtfA
MRVLITGCGSRGDTEPLVALAARLRELGADARMCLPPDYVERCAEVGVPMVPVGRAVRAG
AREPGELPPGAAEVVTEVVAEWFDKVPAAIEGCDAVVTTGLLPAAVAVRSMAEKLGIPYR
YTVLSPDHLPSEQSQAERDMYNQGADRLFGDAVNSHRASIGLPPVEHLYDYGYTDQPWLA
ADPVLSPLRPTDLGTVQTGAWILPDERPLSAELEAFLAAGSTPVYVGFGSSSRPATADAA
KMAIKAVRASGRRIVLSRGWADLVLPDDGADCFVVGEVNLQELFGRVAAAIHHDSAGTTL
LAMRAGIPQIVVRRVVDNVVEQAYHADRVAELGVGVAVDGPVPTIDSLSAALDTALAPEI
RARATTVADTIRADGTTVAAQLLFDAVSLEKPTVPA

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
P96558

# Drug_Target_2_SwissProt_Name:
P96558_AMYOR

# Drug_Target_2_Synonyms:
PCZA361.19

# Drug_Target_2_Theoretical_pI:
4.56

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB00512
